Case Report

A Case of Stent Thrombosis Occurred at 5 Years after Sirolimus-Eluting Stent Implantation

Su A Kim and Sang Yup Lim*

Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea

Drug-eluting stents (DES) have reduced the rate of repeated revascularization of target lesions. For this reason, DES are considered to be superior to bare-metal stents in reducing the restenosis rate. However, some problems have been reported after implantation of DES. One of them, stent thrombosis, has arisen as a fatal complication. Dual antiplatelet therapy is recommended for at least 12 months after implantation of DES to prevent stent thrombosis. Here, we report a case of very late stent thrombosis that occurred 1 week after discontinuation of clopidogrel at 5 years (1832 days) after implantation of a sirolimus-eluting stent.

Key Words: Drug-eluting stent; Thrombosis; Myocardial infarction

INTRODUCTION

In recent studies, drug-eluting stents (DES) were more widely used than bare-metal stents (BMS) in patients who underwent percutaneous coronary intervention (PCI). Recently, several significant complications after implantation of DES have been reported, and stent thrombosis (ST) is a rare but fatal complication among them. Discontinuation of dual antiplatelet therapy is known to be a risk factor for ST in patients after implantation of DES. Therefore, dual antiplatelet therapy is recommended to be maintained for at least 12 months after stent implantation to prevent late stent thrombosis (LST) or very late stent thrombosis (VLST). However, it is still unclear how long dual antiplatelet therapy is needed and when the antiplatelet therapy can be safely stopped.

Here we report a case of a patient with acute myocardial infarction due to VLST that occurred 1 week after discontinuation of 5 years of dual antiplatelet therapy after implantation of a sirolimus-eluting stent.

CASE REPORT

A man with no risk factors for coronary artery disease except smoking underwent PCI in May 2005 at age 44. A 3.0×23 mm Cypher® stent was deployed in the proximal right coronary artery. The patient was placed on aspirin and clopidogrel as antiplatelet therapy. He experienced no adverse events. Five years later, the patient was advised to stop taking clopidogrel. Seven days after the discontinuation of clopidogrel, he experienced severe chest pain and was transported to the emergency room by ambulance. A physical examination revealed a temperature of 36.0°C, blood pressure of 90/60 mmHg, and a regular heart rate of 100 beats/min without murmur or gallop. Pulmonary rales, peripheral edema, or other clinical signs of congestive heart failure were not present. An electrocardiogram revealed ST-segment elevation in lead II, III, and aVF. The peak level of creatine kinase (CK) was 1,334 U/L, CK-MB was 75.4 U/L, and troponin-I was 38.1 ng/ml. Transthoracic echocardiography in the emergency room revealed inferior wall akinesia, and his ejection fraction was 45%. The patient received 300 mg of aspirin and 600 mg of clopidogrel as a loading dose and was transferred to the cardiac catheterization laboratory. His pain to door time was about 60 minutes, and the door to balloon time was 72 minutes. An emergent coronary angiogram revealed a thrombotic total occlusion at the proximal right coronary artery (Fig. 1A). The occluded right coronary artery was revascularized successfully by balloon angioplasty with a 3.0×20 mm balloon (Fig. 1B). After PCI, Ultegra Rapid Platelet Function Assay (RPFA)-ASA and Ultegra RPFA-P2Y12 (VerifyNow™ Assay) were performed to determine aspirin and clopidogrel resistance. Aspirin resistance was defined as an aspirin reaction unit (ARU) ≥ 550. Clopidogrel resistance was defined as per-

*Corresponding Author:
Sang Yup Lim
Department of Internal Medicine,
Korea University Ansan Hospital, 516 Gojan-dong, Danwon-gu, Ansan 425-707, Korea
TEL: +82-31-412-6755
FAX: +82-31-412-5594
E-mail: vnlover@hanmail.net
cent inhibition of P2Y12 less than 20%. The patient's ARU was 350 and his P2Y12 was 70%.

The patient was discharged uneventfully and followed up with dual antiplatelet therapy of aspirin and clopidogrel. There have been no adverse events with clinical follow-up for 1 year, and a follow-up coronary angiogram revealed no significant stent restenosis.

**DISCUSSION**

DES interrupt re-endothelialization of the vessels, which results in a lower rate of target lesion revascularization than with BMS. However, delayed vascular healing after PCI may cause ST. Premature discontinuation of antiplatelet therapy is the most common precipitating factor of ST. Long and multiple stents, stent under-expansion or stent malposition, residual dissection, and resistance to aspirin and clopidogrel have been suggested as other possible causes of ST. Several studies revealed a higher rate of LST and VLST after DES implantation than after BMS implantation. Dual antiplatelet therapy reduces subacute thrombotic events after PCI, and at least 12 months of dual antiplatelet therapy after PCI is recommended in the current guidelines to prevent ST.

However, the duration of dual antiplatelet therapy is not precisely defined. Whether long-term maintenance of dual antiplatelet therapy can prevent LST or VLST is still controversial. Park et al reported that clopidogrel continuation beyond 1 year did not appear to decrease stent thrombosis and clinical events after DES implantation, although Tanzili et al concluded that 2 years of dual antiplatelet therapy can prevent the occurrence of VLST after DES implantation.

Triple antiplatelet therapy adding cilostazol is considered to be another choice for preventing stent thrombosis in patients with clopidogrel resistance or for the prevention of recurrent stent thrombosis. The disadvantage of triple therapy is the bleeding tendency, but the bleeding tendency of triple therapy was reported to be not much higher than that of dual antiplatelet therapy in several studies. However, the effect of triple therapy on long-term survival or cardiac events is controversial as well.

In this patient, there were no risk factors for ST except former smoking and no evidence of aspirin or clopidogrel resistance. The patient had been treated with dual antiplatelet agents for enough time (5 years) after DES implantation, but VLST occurred at 1 week after discontinuation of clopidogrel.

We concluded that 12 months of dual antiplatelet therapy may not be enough for the prevention of LST or VLST after DES implantation in some patients who do not show complete re-endothelialization of the coronary artery. Concerning the decision to cease clopidogrel therapy, we suggest that it should depend on the condition of the patient and risk factors for ST such as underlying disease, the length or location of the lesion, the resistance of aspirin or clopidogrel, and so on. It seems difficult to decide when the dual antiplatelet therapy can be safely stopped. Perhaps the development of imaging systems such as optical coherence tomography will give us more precise information. We suggest that physicians educate their patients about the hazards of premature cessation of dual antiplatelet therapy and delay performing surgical procedures until 1 year after implantation of DES. Further studies are required to prevent LST or VLST after implantation of DES.

**REFERENCES**

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
2. Sibbing D, Laugwitz KL, Bott-Flügel L, Pache J. Very late stent thrombosis 42 months after implantation of sirolimus-eluting stent and discontinuation of antiplatelet therapy. Case Report Med 2009;2009:713292.
3. Joner M, Finn AV, Farb A, Mont EK, Kolidogie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
4. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta
T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.

5. Rossini R, Capodanno D, Lettieri C, Musumeci G, Nijaradze T, Romano M, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011;107:186-94.

6. Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc 2006;81:641-52.

7. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv 2011;4:24-9.

8. Park DW, Yun SC, Lee SW, Kim YH, Lee CW, Hong MK, et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv 2008;1:494-503.

9. Tanzilli G, Greco C, Pelliccia F, Pascori V, Barillà F, Paravati V, et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol 2009;104:1357-61.

10. Chen KY, Rha SW, Li YJ, Poddar KL, Jin Z, Minami Y, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207-14.

11. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011;57:280-9.